Spyre Therapeutics (SYRE) Total Current Liabilities (2015 - 2026)

Spyre Therapeutics' Total Current Liabilities history runs 12 years deep, the most recent figure standing at $85.2 million for Q1 2026.

• Quarterly Total Current Liabilities rose 20.49% year-over-year to $85.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85.2 million (up 20.49% YoY) and the FY2025 annual result came in at $58.7 million, up 8.56% from the prior year.
• Total Current Liabilities was $85.2 million for Q1 2026 at Spyre Therapeutics, up from $58.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $232.2 million in Q2 2023 and bottomed at $12.6 million in Q1 2023.
• A 5-year average of $53.3 million and a median of $44.9 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities soared 1364.09% — and 2024, when it sank 90.47%.
• Spyre Therapeutics' Total Current Liabilities stood at $14.7 million in 2022, then soared by 118.19% to $32.0 million in 2023, then soared by 69.05% to $54.1 million in 2024, then climbed by 8.56% to $58.7 million in 2025, then surged by 45.12% to $85.2 million in 2026.
• Business Quant data shows SYRE's Total Current Liabilities at $85.2 million in Q1 2026, $58.7 million in Q4 2025, and $46.3 million in Q3 2025.